318 -5 (79) 2025 - Vokhidov J.J. - PSORIATIC ARTHRITIS: PATHOGENETIC MECHANISMS AND STRATEGY FOR SELECTING BIOLOGIC THERAPY

PSORIATIC ARTHRITIS: PATHOGENETIC MECHANISMS AND STRATEGY FOR SELECTING BIOLOGIC THERAPY

Vokhidov J.J. - Samarkand State Medical University

Resume

Psoriatic arthritis (PsA) is an immunoinflammatory disease accompanied by musculoskeletal lesions on the background of cutaneous psoriasis. In recent decades, significant progress has been made in understanding the pathogenesis of PsA, in particular, the key role of Th17 cells, proinflammatory cytokines IL-17, IL-23 and tumor necrosis factor α (TNF-α) has been established, which became the basis for the development and widespread use of targeted biological therapy. The diversity of clinical forms of PsA and the variability of response to treatment determine the need for an individualized approach to the choice of therapy. This article presents modern ideas about the pathogenetic mechanisms of PsA, analyzes the mechanisms of action of the main groups of biological drugs, including TNF-α, IL-17, IL-12/23, IL-23 and JAK inhibitors. Special attention is paid to the algorithm of personalized biological drug selection depending on the clinical phenotype of the disease, the presence of comorbid pathology and previous response to therapy. The key provisions of international recommendations and clinical trials are summarized, which may contribute to optimization of therapy and improvement of prognosis in patients with psoriatic arthritis.

Keywords: psoriatic arthritis, interleukin-17, biological therapy, pathogenesis, IL-23, cytokine inhibitors, personalized approach.

First page

1596

Last page

1600

For citation:Vokhidov J.J. - PSORIATIC ARTHRITIS: PATHOGENETIC MECHANISMS AND STRATEGY FOR SELECTING BIOLOGIC THERAPY//New Day in Medicine 5(79)2025 1596-1600 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

1. Gladman D.D., Antoni C.E., Mease P., et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–ii17.
2. Mease P.J., Smolen J.S., Behrens F., et al. A head-to-head comparison of the efficacy and safety of secukinumab and adalimumab in psoriatic arthritis: EXCEED study. Lancet. 2020;395(10235):1496–1505.
3. Coates L.C., Kavanaugh A., Mease P.J., et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2015 treatment recommendations. Arthritis Rheumatol. 2016;68(5):1060–1071.
4. Tsoi L.C., Stuart P.E., Tian C., et al. Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. Nat Commun. 2015;6:7001.
5. Gossec L., Baraliakos X., Kerschbaumer A., et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712.
6. McInnes I.B., Mease P.J., Kirkham B., et al. Secukinumab, a human anti–interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146.
7. Ogdie A., Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545–568.
8. Ritchlin C.T., Colbert R.A., Gladman D.D. Psoriatic arthritis. N Engl J Med. 2017;376(10):957–970.
9. Orbai A.M., de Wit M., Mease P., et al. International patient and physician consensus on a psoriatic arthritis core outcome set. Ann Rheum Dis. 2017;76(4):673–680.
10. Taylor W., Gladman D., Helliwell P., et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665–2673.

    file

    download